Skip to main content
Premium Trial:

Request an Annual Quote

Orchid to Restate Q2, Q3 05 Earnings; Receives Nasdaq Delisting Warning for Missing Filing Deadline

NEW YORK, April 7 (GenomeWeb News) - Orchid Cellmark will restate its earnings for the second and third quarters of 2005 due to a non-cash, non-operating income event during the second quarter, the company said today.


Also, the company has received a delisting warning from Nasdaq for failing to file a financial statement on time, and that its shares will be delisted at the start of business on April 12, according to a filing with the US Securities and Exchange Commission.


Orchid will restate its earnings due to a settlement of escrow claims associated with its December 2001 acquisition of Lifecodes. The 163,259 shares of the company's common stock received from this settlement, valued at $1.6 million, should have been recorded at the settlement date as a non-operating gain and an acquisition of treasury stock, Orchid said.


The restatement will neither impact the company's cash flow nor have a negative effect on its fiscal year 2005 results.


On April 3, Orchid received a delisting warning from Nasdaq because it failed to file its annual report by the extended deadline of March 31. The company has requested a hearing wirth the Nasdaq listing qualifications panel to appeal the delisting notice.


Orchid said it intends to provide its earnings for the fourth quarter and full year 2005, and file its annual report, "at the earliest possible date."

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.